Detalhe da pesquisa
1.
The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
Int J Cancer
; 154(4): 692-700, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37818966
2.
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
BMC Cancer
; 24(1): 16, 2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38166764
3.
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Int J Clin Oncol
; 29(3): 258-265, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38310597
4.
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Eur Arch Otorhinolaryngol
; 2024 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38795147
5.
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
BMC Cancer
; 23(1): 136, 2023 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36765293
6.
Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study.
Neoplasma
; 70(1): 158-165, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36620878
7.
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Cancer Invest
; 40(2): 199-209, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34894960
8.
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.
Anticancer Drugs
; 33(7): 663-670, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35703239
9.
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.
Future Oncol
; 18(23): 2573-2582, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35734870
10.
Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).
Turk J Med Sci
; 52(4): 1022-1032, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36326360
11.
Association of illness perception with chemotherapy-induced nausea and vomiting: a Turkish Oncology Group (TOG) study.
Future Oncol
; 17(15): 1933-1942, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33599548
12.
Is SUVmax of 18F-FDG PET/CT Predictive Factor for Malignancy in Gastrointestinal Tract?
Niger J Clin Pract
; 24(8): 1217-1224, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34397034
13.
Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?
Support Care Cancer
; 28(5): 2273-2282, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31471631
14.
Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
BMC Cancer
; 24(1): 114, 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262962
15.
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
BMC Cancer
; 23(1): 192, 2023 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36849943
16.
Biweekly cisplatin and gemcitabine with two different doses in non small cell lung cancer patients: A retrospective singlecenter experience.
J BUON
; 23(4): 1070-1076, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30358213
17.
Factors affecting survival and treatment efficacy in breast cancer patients with bone marrow metastasis.
Breast J
; 26(4): 815-818, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562662
18.
Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment.
Sci Rep
; 14(1): 10632, 2024 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38724585
19.
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
Expert Opin Pharmacother
; 25(4): 477-484, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38568074
20.
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.
Medicine (Baltimore)
; 103(21): e37972, 2024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38787994